Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.
The Nuclear Factor Erythroid 2 Related Factor 2 – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Nuclear Factor Erythroid 2 Related Factor 2, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nuclear Factor Erythroid 2 Related Factor 2 and features dormant and discontinued projects.
Key Therapy Areas in the Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market
In the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market the key therapy areas are Central Nervous System, Immunology, Gastrointestinal, Metabolic Disorders, Oncology, Cardiovascular, Genito Urinary System and Sex Hormones, Musculoskeletal Disorders, Respiratory, Genetic Disorders, Ophthalmology, Dermatology, Hematological Disorders, Infectious Disease, and Women’s Health.
Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market, by Therapy Areas
For more therapy area insights, download a free report sample
Key MoA in the Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market
Nuclear Factor Erythroid 2 Related Factor 2 Activator has the highest number of pipeline products followed by Nuclear Factor Erythroid 2 Related Factor 2 Inhibitor.
Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market are oral, topical, ophthalmic, intravenous, inhalational, intramuscular, and rectal. Oral has the highest number of pipeline products.
Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market
The key molecule types in the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market are Small Molecule, and Synthetic Peptide.
Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market
The major companies in the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market are Reata Pharmaceuticals Inc, AKL Research and Development Ltd, Annji Pharmaceutical Co Ltd, Anteris Bio, Arbor Pharmaceuticals LLC, Bach Pharma Inc, Bayer AG, BioApex sro, Biogen Inc, Biotoxtech Co Ltd, C4X Discovery Holdings Plc, Cellix Bio Pvt Ltd, Complexa Inc, Cureveda LLC, and Daiichi Sankyo Co Ltd.
Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market Overview
Key Therapy Areas | Central Nervous System, Immunology, Gastrointestinal, Metabolic Disorders, Oncology, Cardiovascular, Genito Urinary System and Sex Hormones, Musculoskeletal Disorders, Respiratory, Genetic Disorders, Ophthalmology, Dermatology, Hematological Disorders, Infectious Disease, and Women’s Health |
Key Mechanisms of action | Nuclear Factor Erythroid 2 Related Factor 2 Activator, and Nuclear Factor Erythroid 2 Related Factor 2 Inhibitor |
Key Routes of Administration | Oral, Topical, Ophthalmic, Intravenous, Inhalational, Intramuscular, and Rectal |
Key Molecule Types | Small Molecule, and Synthetic Peptide |
Major Companies | Reata Pharmaceuticals Inc, AKL Research and Development Ltd, Annji Pharmaceutical Co Ltd, Anteris Bio, Arbor Pharmaceuticals LLC, Bach Pharma Inc, Bayer AG, BioApex sro, Biogen Inc, Biotoxtech Co Ltd, C4X Discovery Holdings Plc, Cellix Bio Pvt Ltd, Complexa Inc, Cureveda LLC, and Daiichi Sankyo Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Nuclear Factor Erythroid 2 Related Factor 2
- The pipeline guide reviews pipeline therapeutics for Nuclear Factor Erythroid 2 Related Factor 2 by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Nuclear Factor Erythroid 2 Related Factor 2 therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Nuclear Factor Erythroid 2 Related Factor 2 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Nuclear Factor Erythroid 2 Related Factor 2
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Nuclear Factor Erythroid 2 Related Factor 2
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Annji Pharmaceutical Co Ltd
Anteris Bio
Arbor Pharmaceuticals LLC
Bach Pharma Inc
Bayer AG
BioApex sro
Biogen Inc
Biotoxtech Co Ltd
C4X Discovery Holdings Plc
Cellix Bio Pvt Ltd
Complexa Inc
Cureveda LLC
Daiichi Sankyo Co Ltd
Erganeo
Evgen Pharma Plc
Haisco Pharmaceutical Group Co Ltd
Immungenetics AG
Ixchel Pharma LLC
Lignamed LLC
Mariposa Therapeutics Ltd
Mochida Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
Rescue Therapeutics Inc
Scohia Pharma Inc
Sulfateq BV
Vitalis LLC
Vividion Therapeutics Inc
vTv Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas in the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market?
In the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market the key therapy areas are Central Nervous System, Immunology, Gastrointestinal, Metabolic Disorders, Oncology, Cardiovascular, Genito Urinary System and Sex Hormones, Musculoskeletal Disorders, Respiratory, Genetic Disorders, Ophthalmology, Dermatology, Hematological Disorders, Infectious Disease, and Women’s Health.
-
What are the key mechanisms of action in the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market?
In the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market the key mechanisms of action are Nuclear Factor Erythroid 2 Related Factor 2 Activator, and Nuclear Factor Erythroid 2 Related Factor 2 Inhibitor.
-
What are the key routes of administration in the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market?
The key routes of administration in the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market are oral, topical, ophthalmic, intravenous, inhalational, intramuscular, and rectal.
-
What are the key molecule types in the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market?
The key molecule types in the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market are Small Molecule, and Synthetic Peptide. Small Molecule has the maximum number of products.
-
What are the major companies in the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market?
In the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market the major companies are Reata Pharmaceuticals Inc, AKL Research and Development Ltd, Annji Pharmaceutical Co Ltd, Anteris Bio, Arbor Pharmaceuticals LLC, Bach Pharma Inc, Bayer AG, BioApex sro, Biogen Inc, Biotoxtech Co Ltd, C4X Discovery Holdings Plc, Cellix Bio Pvt Ltd, Complexa Inc, Cureveda LLC, and Daiichi Sankyo Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.